---
title: "Haleon discloses dividend-driven share purchase by senior independent director"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286785831.md"
description: "Haleon PLC announced that Senior Independent Director Alan Stewart purchased 498 shares at £3.3105 each through a dividend reinvestment on May 14, 2026. This transaction enhances insider alignment with shareholders and increases transparency regarding board shareholdings. The latest analyst rating for Haleon stock (GB:HLN) is a Buy with a £4.15 price target, while TipRanks’ AI Analyst rates it as Neutral due to solid financial performance but weaker near-term momentum."
datetime: "2026-05-18T14:11:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286785831.md)
  - [en](https://longbridge.com/en/news/286785831.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286785831.md)
---

# Haleon discloses dividend-driven share purchase by senior independent director

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Haleon PLC ( (GB:HLN) ) has provided an announcement.

Haleon plc, the London- and New York-listed consumer health group, concentrates exclusively on everyday health products, investing in research and innovation across categories including oral care, pain relief, respiratory and digestive health. Its well-known brands, including Advil, Panadol, Sensodyne and Voltaren, are widely trusted by consumers and recommended by health professionals globally.

The company disclosed that Senior Independent Non-Executive Director Alan Stewart acquired 498 Haleon ordinary shares through a dividend reinvestment on 14 May 2026 at £3.3105 per share. The transaction, reported under UK Market Abuse Regulation, marginally increases insider alignment with shareholders and provides incremental transparency around board-level shareholdings for investors.

The most recent analyst rating on (GB:HLN) stock is a Buy with a £4.15 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

**Spark’s Take on HLN Stock**

According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.

The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.

To see Spark’s full report on HLN stock, click here.

**More about Haleon PLC**

Haleon plc is a global consumer health company focused on improving everyday health through over-the-counter products. Its portfolio spans oral health, vitamins, minerals and supplements, pain relief, respiratory health, digestive health, and therapeutic skin care, with brands such as Advil, Centrum, Panadol, Sensodyne and Voltaren serving more than one billion consumers worldwide.

**Average Trading Volume:** 24,262,692

**Technical Sentiment Signal:** Sell

**Current Market Cap:** £29.52B

For a thorough assessment of HLN stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [HLN.US](https://longbridge.com/en/quote/HLN.US.md)

## Related News & Research

- [Haleon tackles sports injuries with latest soccer play](https://longbridge.com/en/news/286297045.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)
- [Sharon AI Appoints Mr. Andrew Penn as Chairman of the Board of Directors | SHAZ Stock News](https://longbridge.com/en/news/287210261.md)
- [How Beaten-Down Tempus AI Stock Offers a Lottery Ticket for Traders Here](https://longbridge.com/en/news/286786866.md)
- [Intelligent Protection Management Corp. Launches IPM Private Cloud AI Offering | IPM Stock News](https://longbridge.com/en/news/286896871.md)